ArticleInternational journal of nephrology2011
Hemolytic uremic syndrome: new developments in pathogenesis and treatment.
Article in International journal of nephrology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 55 citations in OpenAlex.
- Neurological Manifestations of Hemolytic Uremic Syndrome: A Comprehensive Review.Brain sciences · 2025Review
- Antimicrobial Effects of Plant-Based Supplements on Gut Microbial Diversity in Small Ruminants.Pathogens (Basel, Switzerland) · 2023Review
- Cerebral microstructural changes in children suffering from hemolytic uremic syndrome.European journal of pediatrics · 2023Article
- Genomic Characterization of FecalPathogens (Basel, Switzerland) · 2023Article
- EntericFrontiers in veterinary science · 2022Review
- Rapid Detection of Pathogenic Bacteria by the Naked Eye.Biosensors · 2021Article
- Atypical haemolytic uraemic syndrome: a case of rare genetic mutation.BMJ case reports · 2021Article
- Verotoxin-1-Induced ER Stress Triggers Apoptotic or Survival Pathways in Burkitt Lymphoma Cells.Toxins · 2020Article
- Hemolytic Uremic Syndrome Associated WithMayo Clinic proceedings. Innovations, quality & outcomes · 2018Article
- Short- and Long-Term Renal Outcome of Hemolytic-Uremic Syndrome in Childhood.Frontiers in pediatrics · 2018Article
- Consequences of hemolytic uremic syndrome among hemodialysis patients.Journal of nephrology · 2015Article
- Early erythropoietin in post-diarrheal hemolytic uremic syndrome: a case-control study.Pediatric nephrology (Berlin, Germany) · 2015Article
- High frequency of acquired ADAMTS13 deficiency after hemolysis in Hemiscorpius Lepturus (scorpion) stung children.Indian journal of pediatrics · 2014Article
- Ouabain protects against Shiga toxin-triggered apoptosis by reversing the imbalance between Bax and Bcl-xL.Journal of the American Society of Nephrology : JASN · 2013Article
- Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells.Infection and immunity · 2013Article
- Prevalence in the General Population of a CFH Sequence Variant Associated with Atypical Haemolytic Uraemic Syndrome in an Extensive Family from Southwest England.Nephron extra · 2013Article
- Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation.Pediatric nephrology (Berlin, Germany) · 2012Article
- Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics.Current opinion in nephrology and hypertension · 2012Review
- Emergency management of hypertension in children.International journal of nephrology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemolytic uremic syndrome is defined by the characteristic triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. In children, most cases of HUS are caused by Shiga-toxin-producing bacteria, especially Escherichia coli O157:H7. Common vehicles of transmission include ground beef, unpasteurized milk, and municipal or swimming water. Shiga-toxin-associated HUS is a main cause of acute renal failure in young children. Management remains supportive as there is at present no specific therapy to ameliorate the prognosis. Immediate outcome is most often favourable but long-term renal sequelae are frequent due to nephron loss. Atypical HUS represents 5% of cases. In the past 15 years, mutations in complement regulators of the alternative pathway have been identified in almost 60% of cases, leading to excessive complement activation. The disease has a relapsing course and more than half of the patients either die or progress to end-stage renal failure. Recurrence after renal transplantation is frequent.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.